More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Cabozantinib [849217-68-1]
Chemical Structure
Chemical Structure
Chemical Structure

Cabozantinib [849217-68-1]

Research Use Only
CDX-C0755
Chemodex
CAS Number849217-68-1
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight501.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    Chemodex
  • Product Name
    Cabozantinib [849217-68-1]
  • Delivery Days Customer
    10
  • CAS Number
    849217-68-1
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C28H24FN3O5
  • Molecular Weight
    501.5
  • Scientific Description
    Cabozantinib is a potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of endothelial growth factor receptor 2 (VEGFR2) (IC50=0.035nM), the hepatocyte growth factor receptor c-Met (IC50=1.3nM), AXL (IC50=7nM), fms like tyrosine kinase 3 (FLT3) (IC50=11.3nM), mast/stem cell growth factor (KIT) (IC50=4.6nM), RET (IC50=5.2nM), tyrosine-protein kinase receptor (TIE-2) (IC50=14.3nM) and RON (IC50=124nM). Cabozantinib reduces cell proliferation and vascular density. It also induces apoptosis and intratumoral hypoxia. Cabozantinib exhibits dose-related tumor growth inhibition, tumor regression, angiogenesis and/or metastasis inhibition in a broad range of preclinical tumor models. The anticancer compound cabozantinib has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and glioblastoma. - Chemical. CAS: 849217-68-1. Formula: C28H24FN3O5. MW: 501.5. Cabozantinib is a potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of endothelial growth factor receptor 2 (VEGFR2) (IC50=0.035nM), the hepatocyte growth factor receptor c-Met (IC50=1.3nM), AXL (IC50=7nM), fms like tyrosine kinase 3 (FLT3) (IC50=11.3nM), mast/stem cell growth factor (KIT) (IC50=4.6nM), RET (IC50=5.2nM), tyrosine-protein kinase receptor (TIE-2) (IC50=14.3nM) and RON (IC50=124nM). Cabozantinib reduces cell proliferation and vascular density. It also induces apoptosis and intratumoral hypoxia. Cabozantinib exhibits dose-related tumor growth inhibition, tumor regression, angiogenesis and/or metastasis inhibition in a broad range of preclinical tumor models. The anticancer compound cabozantinib has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and glioblastoma.
  • SMILES
    O=C(NC1=CC=C(OC2=C3C=C(C(OC)=CC3=NC=C2)OC)C=C1)C4(C(NC5=CC=C(C=C5)F)=O)CC4
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200